Response Assessement of Lutetium-177-PSMA-Targeted Radionuclide Therapy for Advanced Metastatic Prostate Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013665

Enrollment

125

Registered

2017-12-28

Start date

2017-12-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: the response of patients treated with Lutetium-177-PSMA-Targeted Radionuclide Therapy in the Department of nuclear medicine Universitätsklinikum Freiburg is evaluated on the basis of laborche

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients treated with Lutetium-177-PSMA-Targeted Radionuclide Therapy in the Department of nuclear medicine Universitätsklinikum Freiburg btween 07/15 and 12/17.

Exclusion criteria

Exclusion criteria: patients for whom sufficient data acquisition could not be accomplished

Design outcomes

Primary

Measure	Time frame
evaluation of serologic and imaging response to Lutetium-177-PSMA-Targeted Radionuclide Therapy	—

Secondary

Measure	Time frame
assessement of clinical response to Lutetium-177-PSMA-Targeted Radionuclide Therapy (pain, quality of life)	—

Countries

Germany

Contacts

Public ContactJuri Ruf

University Clinic FreiburgDepartment of Nuclear Medicine

juri.ruf@uniklinik-freiburg.de0761 270-39990

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 18, 2026